Welcome to LookChem.com Sign In|Join Free

CAS

  • or

1626-12-6

Post Buying Request

1626-12-6 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

1626-12-6 Usage

Class of compound

Pyridine

Functional group

Amine

Physical state

Pale yellow solid

Solubility

Not very soluble in water, dissolves readily in organic solvents

Uses

Production of pharmaceuticals and agrochemicals as a building block for various compounds

Potential applications

Organic synthesis, medicinal chemistry, and biological activities for further study and development.

Check Digit Verification of cas no

The CAS Registry Mumber 1626-12-6 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 1,6,2 and 6 respectively; the second part has 2 digits, 1 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 1626-12:
(6*1)+(5*6)+(4*2)+(3*6)+(2*1)+(1*2)=66
66 % 10 = 6
So 1626-12-6 is a valid CAS Registry Number.

1626-12-6SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 17, 2017

Revision Date: Aug 17, 2017

1.Identification

1.1 GHS Product identifier

Product name 2,2,8-trimethyl-4H-[1,3]dioxino[4,5-c]pyridin-5-amine

1.2 Other means of identification

Product number -
Other names 2,2,8-trimethyl-4H-[1,3]dioxino[4,5-c]pyridin-5-ylamine

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:1626-12-6 SDS

1626-12-6Relevant articles and documents

Dual antiplatelet/anticoagulant pyridoxine analogs

-

Page/Page column 42, (2008/06/13)

Compounds with antiplatelet aggregation and anticoagulant characteristics for the treatment of cardiovascular, cerebrovascular, and cardiovascular related diseases and symptoms, are described. The methods are directed to administering pharmaceutical compo

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 1626-12-6